Template:SUIT-002 pce: Difference between revisions

From Bioblast
No edit summary
No edit summary
ย 
(7 intermediate revisions by 4 users not shown)
Line 1: Line 1:
[[Image:SUIT-MitoFit.png|right|190px|link=http://www.bioblast.at/index.php/MitoPedia:_SUIT |MitoPedia: SUIT]]
[[Image:SUIT-MitoFit.png|right|190px|link=http://www.bioblast.at/index.php/MitoPedia:_SUIT |MitoPedia: SUIT]]
== Steps and respiratory states ==
== Steps and respiratory states ==
[[File:ce1;1Dig;1D;2M.1;3Oct;3c;4M2;5P;6G;7S;8Gp;9U;10Rot-.png|400px]]
[[File:ce1;1Dig;1D;2M.1;3Oct;3c;4M2;5P;6G;7S;8Gp;9U;10Rot;11Ama;12AsTm;13Azd.png|400px]]


{{Template:SUIT cells}}
{{Template:SUIT cells}}
Line 10: Line 10:
|-
|-
| 1D
| 1D
| [[ROX]]
| [[REN]]
| ย 
| ย 
| ย 
| ย 
| ADP is added to stimulate consumption of endogenous fuel-substrates.
| 1D


{{Template:SUIT ROX}}
* {{Template:SUIT ADP endogenous substrates}}


|-
|-
Line 22: Line 22:
|
|
| ย 
| ย 
| {{Template:SUIT M_low}}
| ย 
ย 
*{{Template:SUIT M_low}}


|-
|-
| 3Oct
| 3Oct
| [[Octanoylcarnitine|Oct]]<sub>''P''</sub>
| [[OctM]]<sub>''P''</sub>
| ([[F]])
| [[F]]
| FAO
| FAO
| 1D;2M.1;3Oct
| 1D;2M.1;3Oct


{{Template:SUIT F}} ย 
*{{Template:SUIT F}} ย 


|-
|-
Line 40: Line 42:
| 1D;2M.1;3Oct;3c
| 1D;2M.1;3Oct;3c


{{Template:SUIT F}} {{Template:SUIT OXPHOS}} {{Template:SUIT c}}
*{{Template:SUIT F}} ย 
*{{Template:SUIT OXPHOS}} ย 
*{{Template:SUIT c}}


|-
|-
| 4M2
| 4M2
| [[OctM]]<sub>''P''</sub>
| [[OctM]]<sub>''P''</sub>
| [[F]]
| [[Fatty_acid_oxidation_pathway_control_state|F(N)]]
| FAO
| FAO
| 1D;2M.1;3Oct;4M2;5P;6G;7S;8Gp;9U;10Rot
| 1D;2M.1;3Oct;4M2;5P;6G;7S;8Gp;9U;10Rot


{{Template:SUIT F}} {{Template:SUIT M_high}} {{Template:SUIT OXPHOS}} ย 
*{{Template:SUIT F}} ย 
*{{Template:SUIT M_high}} ย 
*{{Template:SUIT OXPHOS}} ย 


|-
|-
Line 58: Line 64:
| 1D;2M.1;3Oct;4M2;5P
| 1D;2M.1;3Oct;4M2;5P


{{Template:SUIT N}} {{Template:SUIT OXPHOS}}
*{{Template:SUIT N}}
* {{Template:SUIT OXPHOS}}


|-
|-
Line 67: Line 74:
| 1D;2M.1;3Oct;4M2;5P;6G
| 1D;2M.1;3Oct;4M2;5P;6G


{{Template:SUIT N}} {{Template:SUIT OXPHOS}}
*{{Template:SUIT N}} ย 
*{{Template:SUIT OXPHOS}}


|-
|-
Line 76: Line 84:
| 1D;2M.1;3Oct;4M2;5P;6G;7S
| 1D;2M.1;3Oct;4M2;5P;6G;7S


{{Template:SUIT FNS}} {{Template:SUIT OXPHOS}}
*{{Template:SUIT FNS}} ย 
*{{Template:SUIT OXPHOS}}


|-
|-
Line 85: Line 94:
| 1D;2M.1;3Oct;4M2;5P;6G;7S;8Gp
| 1D;2M.1;3Oct;4M2;5P;6G;7S;8Gp


{{Template:SUIT FNSGp}} {{Template:SUIT OXPHOS}}
*{{Template:SUIT FNSGp}} ย 
*{{Template:SUIT OXPHOS}}


|-
|-
Line 94: Line 104:
| 1D;2M.1;3Oct;4M2;5P;6G;7S;8Gp;9U
| 1D;2M.1;3Oct;4M2;5P;6G;7S;8Gp;9U


{{Template:SUIT FNSGp}} {{Template:SUIT U*}}
*{{Template:SUIT FNSGp}} ย 
*{{Template:SUIT U*}}


|-
|-
Line 103: Line 114:
| 1D;2M.1;3Oct;4M2;5P;6G;7S;8Gp;9U;10Rot
| 1D;2M.1;3Oct;4M2;5P;6G;7S;8Gp;9U;10Rot


{{Template:SUIT SGp}} {{Template:SUIT ET}}
*{{Template:SUIT SGp}} ย 
*{{Template:SUIT ET}}


|-
|-
Line 110: Line 122:
| ย 
| ย 
| ย 
| ย 
| {{Template:SUIT Ama}}
| 1D;2M.1;3Oct;4M2;5P;6G;7S;8Gp;9U;10Rot;11Ama
*{{Template:SUIT Ama}}


|}
|}


{{Template:SUIT CIV}}
{{Template:SUIT CIV}}
{{Template:Keywords in SUIT protocols}}
{{Keywords: SUIT protocols}}

Latest revision as of 17:12, 24 January 2024

MitoPedia: SUIT

Steps and respiratory states

Ce1;1Dig;1D;2M.1;3Oct;3c;4M2;5P;6G;7S;8Gp;9U;10Rot;11Ama;12AsTm;13Azd.png

Step State Pathway Q-junction Comment - Events (E) and Marks (M)
ce1 ROUTINE ce1
  • ROUTINE respiration in the physiological coupling state R. Externally added permeable substrates could contribute to this respiratory state.
1Dig REN ce1;1Dig
  • Optimum effective digitonin concentration for complete plasma membrane permeabilization.
Step State Pathway Q-junction Comment - Events (E) and Marks (M)
1D REN 1D
  • ADP is added to stimulate the consumption of endogenous fuel-substrates.
2M.1
3Oct OctMP F FAO 1D;2M.1;3Oct
  • Respiratory stimulation of the FAO-pathway, F, by fatty acid, FA, in the presence of malate, M. Malate is a type N substrate (N), required for the F-pathway. The FA concentration has to be optimized to saturate the F-pathway, without inhibiting or uncoupling respiration.
3c OctMcP F FAO 1D;2M.1;3Oct;3c
  • Respiratory stimulation of the FAO-pathway, F, by fatty acid, FA, in the presence of malate, M. Malate is a type N substrate (N), required for the F-pathway. The FA concentration has to be optimized to saturate the F-pathway, without inhibiting or uncoupling respiration.
  • OXPHOS capacity P (with saturating [ADP]), active OXPHOS state.
  • Addition of cytochrome c yields a test for integrity of the mtOM (cytochrome c control efficiency). Stimulation by added cytochrome c would indicate an injury of the mtOM and limitation of respiration in the preceding state without added c due to loss of cytochrome c. Typically, cytochrome c is added immediately after the earliest ADP-activation step (OXPHOS capacity P with saturating [ADP]).
4M2 OctMP F(N) FAO 1D;2M.1;3Oct;4M2;5P;6G;7S;8Gp;9U;10Rot
  • Respiratory stimulation of the FAO-pathway, F, by fatty acid, FA, in the presence of malate, M. Malate is a type N substrate (N), required for the F-pathway. The FA concentration has to be optimized to saturate the F-pathway, without inhibiting or uncoupling respiration.
  • High concentration of malate, typically 2 mM, saturates the N-pathway.
  • OXPHOS capacity P (with saturating [ADP]), active OXPHOS state.
5P OctPMP FN F&CI 1D;2M.1;3Oct;4M2;5P
6G OctPGMP FN F&CI 1D;2M.1;3Oct;4M2;5P;6G
7S OctPGMSP FNS F&CI&II 1D;2M.1;3Oct;4M2;5P;6G;7S
  • Respiratory stimulation by simultaneous action of the F-pathway, N-pathway, and S-pathway, with convergent electron flow in the FNS-pathway for reconstitution of TCA cycle function and additive or inhibitory effect of F.
  • OXPHOS capacity P (with saturating [ADP]), active OXPHOS state.
8Gp OctPGMSGpP FNSGp F&CI&II&GpDH 1D;2M.1;3Oct;4M2;5P;6G;7S;8Gp
9U OctPGMSGpE FNSGp F&CI&II&GpDH 1D;2M.1;3Oct;4M2;5P;6G;7S;8Gp;9U
10Rot SGpE SGp CII&GpDH 1D;2M.1;3Oct;4M2;5P;6G;7S;8Gp;9U;10Rot
  • Respiratory stimulation by action of succinate and glycerophosphate, Gp, with convergent electron flow in the SGp-pathway (CII&GpDH-linked pathway to the Q-junction).
  • Noncoupled electron transfer state, ET state, with ET capacity E.
11Ama ROX 1D;2M.1;3Oct;4M2;5P;6G;7S;8Gp;9U;10Rot;11Ama
  • Rox is the residual oxygen consumption in the ROX state, due to oxidative side reactions, estimated after addition of antimycin A (inhibitor of CIII). Rox is subtracted from oxygen flux as a baseline for all respiratory states, to obtain mitochondrial respiration (mt).
Step Respiratory state Pathway control ET-Complex Comment
## AsTm AsTmE CIV CIV
## Azd CHB


Questions.jpg


Click to expand or collaps
Bioblast links: SUIT protocols - >>>>>>> - Click on [Expand] or [Collapse] - >>>>>>>
Cookies help us deliver our services. By using our services, you agree to our use of cookies.